πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 376 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 8114851

Method and medicament for inhibiting the expression of a given gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Feb 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8114984

RNAi modulation of Aha and therapeutic uses thereof

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Feb 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8114981

Method and medicament for inhibiting the expression of a given gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Feb 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 09 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8110674

Therapeutic compositions

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Feb 07 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 02 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8106022

Carbohydrate conjugates as delivery agents for oligonucleotides

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jan 31 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8101584

Method and medicament for inhibiting the expression of a given gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jan 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8101742

Method and medicament for inhibiting the expression of a given gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jan 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8080532

Compositions and methods for inhibiting expression of Huntingtin gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Dec 20 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 15 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8058257

Compositions and methods for inhibiting expression of a gene from the JC virus

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8034793

RNAi modulation of MLL-AF4 and uses thereof

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Oct 11 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 06 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8034376

Lipid containing formulations

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Oct 11 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 06 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8017763

Chemically modified oligonucleotides

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Sep 13 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 08 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8017762

Modified iRNA agents

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Sep 13 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 08 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8013136

Oligonucleotides comprising a non-phosphate backbone linkage

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Sep 06 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 01 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8003619

Method of stimulating an immune response and inhibiting expression of a gene using an olig

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Aug 23 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 18 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7994309

Compositions and methods for inhibiting expression of a mutant gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Aug 09 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 04 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7994307

RNAi modulation of the BCR-ABL fusion gene and uses thereof

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Aug 09 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 04 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7985581

Multiple RNA polymerase III promoter expression constructs

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jul 26 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 21 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7981869

RNAi modulation of RSV and therapeutic uses thereof

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jul 19 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 14 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7956177

dsRNA compositions and methods for treating HPV infection

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jun 07 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 02 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7947659

iRNA agents targeting VEGF

Alnylam Pharmaceuticals, Inc. Β· Granted Tue May 24 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 19 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7928217

Nuclease resistant double-stranded ribonucleic acid

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Apr 19 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 14 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7919473

IRNA agents targeting VEGF

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Apr 05 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 7906484

Complex for transferring an anionic substance into a cell

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Mar 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted